KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q1 2017 13F Holders as of 31 Mar 2017
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 7,587,480
- Share change
- +259,060
- Total reported value
- $59,162,000
- Price per share
- $7.81
- Number of holders
- 18
- Value change
- +$2,023,038
- Number of buys
- 7
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
|
Company |
5.7%
|
2,901,927
|
$20,517,000 | — | 31 Dec 2016 | |
| SV Health Investors, LLC |
13F
|
Company |
5.1%
|
2,579,490
|
$18,237,000 | — | 31 Dec 2016 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
1.2%
|
591,070
|
$4,179,000 | — | 31 Dec 2016 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.65%
|
329,942
|
$2,333,000 | — | 31 Dec 2016 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.64%
|
322,436
|
$2,186,000 | — | 31 Dec 2016 | |
| Vivo Capital, LLC |
13F
|
Company |
0.59%
|
300,325
|
$2,123,000 | — | 31 Dec 2016 | |
| VHCP Management II, LLC |
13F
|
Company |
0.44%
|
221,651
|
$1,322,000 | — | 31 Dec 2016 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.08%
|
39,296
|
$278,000 | — | 31 Dec 2016 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.03%
|
16,346
|
$116,000 | — | 31 Dec 2016 | |
| FIRST QUADRANT LLC/CA |
13F
|
Company |
0.03%
|
12,750
|
$90,000 | — | 31 Dec 2016 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.02%
|
11,483
|
$81,000 | — | 31 Dec 2016 | |
| BlackRock Fund Advisors |
13F
|
Company |
0%
|
2,274
|
$16,000 | — | 31 Dec 2016 | |
| UBS Group AG |
13F
|
Company |
0%
|
909
|
$6,000 | — | 31 Dec 2016 | |
| BlackRock Institutional Trust Company, N.A. |
13F
|
Company |
0%
|
362
|
$3,000 | — | 31 Dec 2016 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0%
|
310
|
$3,000 | — | 31 Dec 2016 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
263
|
$2,000 | — | 31 Dec 2016 | |
| BLACKROCK ADVISORS LLC |
13F
|
Company |
0%
|
258
|
$2,000 | — | 31 Dec 2016 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
159
|
$1,000 | — | 31 Dec 2016 | |
| Creative Planning |
13F
|
Company |
0%
|
142
|
$1,000 | — | 31 Dec 2016 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2017
As of 31 Mar 2017,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,587,480 shares.
The largest 10 holders included
Novo A/S, SV Health Investors, LLC, RA CAPITAL MANAGEMENT, LLC, INTERWEST VENTURE MANAGEMENT CO, INTERNATIONAL BIOTECHNOLOGY TRUST PLC, Vivo Capital, LLC, VHCP Management II, LLC, VANGUARD GROUP INC, EVENTIDE ASSET MANAGEMENT, LLC, and BOOTHBAY FUND MANAGEMENT, LLC.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2017 vs Q4 2016 Across Filers
Q4 2016 holders
18
Q1 2017 holders
18
Holder diff
0
| Investor | Q4 2016 Shares | Q1 2017 Shares | Share Diff | Share Chg % | Q4 2016 Value $ | Q1 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.